Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
157
days
Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study
Authors
Sigal Kaplan; Julie de Nascimento; Andrea ContiniShow moreShow less
Affiliations
1. Epidemiology, Teva Pharmaceutical Industries Ltd., Netanya, Israel; 2. IQVIA, Real World Data, Paris, FranceShow moreShow less
8
days
Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence
Authors
Mohamed A. Elhawary; Brian Edwards; Hadir Rostom; Shanthi N. Pal; Viola Macolic Sarinic; Priya Bahri; Deirdre McCarthy; Victoria Prudence Nambasa; Linda Härmark; Andrew Bate; Rebecca Chandler; Marco Tuccori; Fawaz Alharbi; Mohammed Fouda; Comfort Ogar; Jürgen Beckmann; Jayesh Pandit; Mayada Alkhakany; Christina Saad; Manal M. Younus; Ivor Ralph Edwards; Omar AimerShow moreShow less
Affiliations
1. Egyptian Ministry of Health and Population (General Secretary of ISoP Egypt Chapter), Cairo, Egypt; 2. Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; 3. International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK; 4. Husoteria Consultancy Ltd, London, UK; 5. International Society of Pharmacovigilance-Egypt Chapter, Cairo, Egypt; 6. Faculty of Pharmacy, MSA University, Giza, Egypt; 7. Regulation and Safety, World Health Organization, Geneva, Switzerland; 8. European Medicines Agency, Amsterdam, The Netherlands; 9. International Society of Pharmacovigilance, Special Interest Group on Medicinal Product Risk Communication, Geneva, Switzerland; 10. Gates Foundation, Seattle, USA; 11. African Union Development Agency-NEPAD, Johannesburg, South Africa; 12. Drug Safety Research Unit, Southampton, UK; 13. Global Safety, GSK, Middlesex, UK; 14. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; 15. Coalition for Epidemic Preparedness Innovations, Oslo, Norway; 16. Section of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; 17. Regional Centre of Pharmacovigilance-Veneto Region, Verona, Italy; 18. Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 19. United States Pharmacopeia, Rockville, USA; 20. Berlin, Germany; 21. International Society of Pharmacovigilance Africa Chapter, Nairobi, Kenya; 22. Bayer Healthcare, Nairobi, Kenya; 23. International Society of Pharmacovigilance Patient Engagement Special Interest Group, London, UK; 24. Seven D Consultancy, Dubai, UAE; 25. Bayer Pharmaceuticals Inc., Cairo, Egypt; 26. International Society of Pharmacovigilance Middle East Chapter, Baghdad, Iraq; 27. Iraqi Pharmacovigilance Centre, Ministry of Health, Baghdad, Iraq; 28. Gothenburg, Sweden; 29. InnoVigilance, Laval, CanadaShow moreShow less
70
days
Incidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital
Authors
Anja Jungo; Kanchan Dongre; Delia Halbeisen; Tobias Schneider; Sibylle Chettata; Niklaus Gygli; Murat Bilici; Christoph R. Meier; Anne B. Leuppi-TaegtmeyerShow moreShow less
Affiliations
1. Department of Pharmaceutical Science, University of Basel, Basel, Switzerland; 2. Department of Patient Safety, Medical Directorate, University Hospital Basel, Basel, Switzerland; 3. Department of Clinical Research, University of Basel, Basel, Switzerland; 4. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; 5. Clinic for Anaesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland; 6. Department of Nursing, Medical Directorate, University Hospital Basel, Basel, Switzerland; 7. Department of Quality Management, Medical Directorate, University Hospital Basel, Basel, SwitzerlandShow moreShow less
111
days
Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel
Authors
E Lyn Lee; Fraser Ogle; Jyadeep Nagra; Sofia Su Ye; Jeff Harrison; Joanne BarnesShow moreShow less
Affiliations
1. School of Pharmacy, University of Auckland, Auckland, New ZealandShow moreShow less
127
days
Educational Interventions Affecting Medication Error Reporting by Healthcare Professionals in Secondary and Tertiary Care: A Systematic Review and Narrative Synthesis
Authors
Manahil M. Monshi; Zahraa Jalal; Jeff Aston; Sarah K. Pontefract; Anthony R. CoxShow moreShow less
Affiliations
1. Department of Pharmacy, School of Health Sciences, University of Birmingham, Birmingham, UK; 2. Yanbu General Hospital, Yanbu, Madina Health Cluster, Al Madinah Al Munawwarah, Saudi Arabia; 3. Pharmacy Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKShow moreShow less
141
days
Risk of Fetal Exposure to Teratogenic Medications: Development of Evidence for the Teratogenic Risk Impact and Mitigation (TRIM) Tool
Authors
Yanning Wang; Celeste L. Y. Ewig; Nicole E. Smolinski; Gita A. Toyserkani; Cynthia LaCivita; Esther H. Zhou; Gerald J. Dal Pan; Thuy Nhu Thai; Judith C. Maro; Sonja A. Rasmussen; Almut G. WintersteinShow moreShow less
Affiliations
1. Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, USA; 2. Center for Drug Evaluation and Safety, University of Florida, Gainesville, USA; 3. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA; 4. Independent, Potomac, USA; 5. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, USA; 6. Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA; 7. Department of Epidemiology, University of Florida, Gainesville, USAShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days